Benralizumab is part of a new generation of drugs aimed at people who don’t respond to current treatments. It will be available through the NHS later in 2018.
“This new drug offers a beacon of hope to thousands of people in the UK who have an acute form of asthma called severe eosinophilic asthma” - Kay Boycott, Chief Executive, Asthma UK
Eosinophilic Asthma is a type of asthma caused by an immune cell – eosinophils – that can invade the lungs and cause inflammation. It is thought to affect around 40% of people with severe asthma.
Thanks to your incredible support, Asthma UK were able to input into NICE’s approval process and present the experiences of people living with asthma to them - helping ensure Benralizumab’s successful approval.
With your continued support, we can carry on fighting for people to have access to new asthma treatments, and help fund the development of new drugs and treatments in the future.
“This drug has the potential to transform the quality of lives of many. NHS England now must ensure this treatment become readily available to those who need it.”
- Kay Boycott, Chief Executive, Asthma UK